Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®)–Health Professional Version
SECTIONS
- General Information About Mycosis Fungoides (Including Sézary Syndrome)
- Cellular Classification of Mycosis Fungoides (Including Sézary Syndrome)
- Stage Information for Mycosis Fungoides (Including Sézary Syndrome)
- Treatment Option Overview for Mycosis Fungoides (Including Sézary Syndrome)
- Stage I and Stage II Mycosis Fungoides Treatment
- Stage III and Stage IV Mycosis Fungoides (Including Sézary Syndrome) Treatment
- Recurrent Mycosis Fungoides (Including Sézary Syndrome) Treatment
- Key References for Mycosis Fungoides (Including Sézary Syndrome)
- Changes to This Summary (05/04/2018)
- About This PDQ Summary
- View All Sections
Changes to This Summary (05/04/2018)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Added Wilcox as reference 1.
Added text to state that another report on 4,459 patients from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program database found that the 19.2% of African Americans with mycosis fungoides have a shorter overall survival, potentially attributable to disease characteristics, socioeconomic status, and type of therapy (cited Su et al. as reference 16).
This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.
No hay comentarios:
Publicar un comentario